STAb-T Cells: Bridging Cell Therapy & Bispecific Antibodies for Sustained Antitumour Immunity

• Explore how STAb-T cells combine the precision of cell therapy with the versatility of bispecific antibodies to achieve durable tumour control
• Highlight emerging preclinical data demonstrating their potential to enhance targeting breadth and induce sustained responses

Speakers:

Carolina Pola

Chief Executive Officer

Stab Therapeutics